Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.63 |
| ▸ | LCK | P06239 | 3/20 | 0.63 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.63 |
| ▸ | CDK1 | P06493 | 2/20 | 0.63 |
| ▸ | ROS1 | P08922 | 2/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.63 |
| ▸ | CDK2 | P24941 | 2/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.63 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.63 |
| ▸ | CLK2 | P49760 | 2/20 | 0.63 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.63 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.63 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.63 |
| ▸ | CDC7 | O00311 | 1/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020470 | 1.00 | JAK2 (0.63) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL4828085 | 0.93 | JAK2 (0.64) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL17339446 | 0.93 | JAK2 (0.64) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL4825086 | 0.92 | LCK (0.70) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL4824503 | 0.89 | SRC (0.65) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL31612025 | 0.88 | LCK (0.64) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL5812789 | 0.88 | LCK (0.64) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL7000569 | 0.85 | SRC (0.61) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL29388058 | 0.84 | SRC (0.57) | JAK2LCKSRCDYRK3CDK1 | |
| SCHEMBL19500716 | 0.84 | JAK2 (0.58) | JAK2LCKSRCDYRK3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | JAK2 1515/4885LCK 1534/4885SRC 2167/4885 |
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | JAK2 2736/4885LCK 3550/4885SRC 1649/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | JAK2 3744/4885LCK 1980/4885SRC 1332/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | JAK2 1212/4885LCK 1011/4885SRC 1834/4885 |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | JAK2 322/4885LCK 111/4885SRC 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.